Related references
Note: Only part of the references are listed.Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy
Daolu Yuwen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)
ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients
Yasmeen Razvi et al.
SUPPORTIVE CARE IN CANCER (2019)
Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy
Ikuto Tsukiyama et al.
CANCER SCIENCE (2018)
Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer
Fang Wu et al.
CLINICAL LUNG CANCER (2018)
Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy
Lee S. Schwartzberg et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents
Karin Jordan et al.
SUPPORTIVE CARE IN CANCER (2017)
Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review
Silvia Sommariva et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
Matti Aapro et al.
ONCOLOGIST (2015)
Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy
Praveen Ranganath et al.
BIOMED RESEARCH INTERNATIONAL (2015)
LUNG CANCER IN 2014 Optimizing lung cancer treatment approaches
Rafael Rosell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy
Shota Hamada et al.
SUPPORTIVE CARE IN CANCER (2014)
Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy
H. F. Gao et al.
INTERNAL MEDICINE JOURNAL (2013)
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
I. N. Olver et al.
SUPPORTIVE CARE IN CANCER (2013)
Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study
Costantine Albany et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Aprepitant: drug-drug interactions in perspective
M. S. Aapro et al.
ANNALS OF ONCOLOGY (2010)
Gastrointestinal toxicity of chemotherapeutic agents
EP Mitchell
SEMINARS IN ONCOLOGY (2006)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
